Eugenia Wachters appointed Chief Operating Officer at ProFactor Pharma
Roslin based life sciences company strengthens senior management team.
ProFactor Pharma Ltd (PFP) is excited to welcome Eugenia Wachters, who joined the company as Chief Operating Officer on 1st July 2023. Eugenia will be responsible for leading the company’s business operations, working closely with the PFP Executive team and Board to manage the product development and commercialisation partnership with BioFarma Indonesia (BFI) and to develop a commercial strategy and executable plan for bringing PFP’s highly valuable Factor VIII to Haemophilia A patients in underserved markets.
ProFactor Pharma secured the partnership with BFI in October 2022, worth $3M plus royalties on future sales. Following investment from Kelvin Capital and Scottish Enterprise and the company is now preparing to launch a Series A round to fund clinical development in collaboration with BFI prior to taking the product to market.
Eugenia brings a wealth of experience in the commercialisation of pharmaceuticals world- wide with Sanofi as, variously, General Manager (NL) & Business Unit Director (Benelux), Vice President Business Operations for Emerging markets (France) and General Manager (General Medicines Business) in the UK. More recently she was VP Commercial & Operations with the AI driven Drug Discovery start-up Healx. Eugenia’s experience in developing and executing commercial strategies, driving company Operations and working with local teams and business partners in emerging markets will be of great value to PFP.
She has an MSc Biology (majoring in Biochemistry & Molecular Biology) from the University of Leiden, the Netherlands and an Executive MBA from the Rotterdam School of Management (RSM), the Netherlands.
Jaymin Amin, CEO said “Eugenia’s broad skill set will be a key resource for us and, in particular her experience in developing and executing commercial strategies and launching new products in emerging markets, will be critical to PFP’s mission to provide treatment to the 70% of the world’s Haemophilia A sufferers currently untreated.”
Eugenia said, “I am very excited to be joining PFP at this pivotal moment in the development of an affordable Factor VIII for Haemophilia A patients in underserved markets, combining my passion for and experience in emerging markets, rare disease and commercial operations.”
Angus Hay, Director at Kelvin Capital said, “The addition of Eugenia to the PFP team will bring in-depth knowledge to the commercialisation of PFP’s FVIII product. The technology created by the team will be life changing for those requiring treatment in underserved markets. After working with ProFactor Pharma for a number of years, I am delighted to see the company reach this important stage in its growth journey.”
